JP6663909B2 - オレキシンレセプターモジュレーターとしてのジフルオロピロリジン - Google Patents
オレキシンレセプターモジュレーターとしてのジフルオロピロリジン Download PDFInfo
- Publication number
- JP6663909B2 JP6663909B2 JP2017506968A JP2017506968A JP6663909B2 JP 6663909 B2 JP6663909 B2 JP 6663909B2 JP 2017506968 A JP2017506968 A JP 2017506968A JP 2017506968 A JP2017506968 A JP 2017506968A JP 6663909 B2 JP6663909 B2 JP 6663909B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- acceptable salt
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037024P | 2014-08-13 | 2014-08-13 | |
| US62/037,024 | 2014-08-13 | ||
| PCT/US2015/044974 WO2016025669A1 (en) | 2014-08-13 | 2015-08-13 | Difluoropyrrolidines as orexin receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524005A JP2017524005A (ja) | 2017-08-24 |
| JP2017524005A5 JP2017524005A5 (enExample) | 2018-09-20 |
| JP6663909B2 true JP6663909B2 (ja) | 2020-03-13 |
Family
ID=55304607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506968A Active JP6663909B2 (ja) | 2014-08-13 | 2015-08-13 | オレキシンレセプターモジュレーターとしてのジフルオロピロリジン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10221170B2 (enExample) |
| EP (1) | EP3180332B1 (enExample) |
| JP (1) | JP6663909B2 (enExample) |
| AR (1) | AR101558A1 (enExample) |
| ES (1) | ES2901418T3 (enExample) |
| TW (1) | TW201613902A (enExample) |
| UY (1) | UY36272A (enExample) |
| WO (1) | WO2016025669A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| KR20230116948A (ko) | 2016-03-10 | 2023-08-04 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
| CN106278918B (zh) * | 2016-08-12 | 2018-05-11 | 合肥久诺医药科技有限公司 | 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法 |
| JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP7012703B2 (ja) * | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CN111132975B (zh) * | 2017-09-28 | 2023-05-23 | 勃林格殷格翰国际有限公司 | N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺 |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
| TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| US11208892B2 (en) | 2020-01-17 | 2021-12-28 | Raytheon Technologies Corporation | Rotor assembly with multiple rotor disks |
| US11434771B2 (en) | 2020-01-17 | 2022-09-06 | Raytheon Technologies Corporation | Rotor blade pair for rotational equipment |
| US11339673B2 (en) | 2020-01-17 | 2022-05-24 | Raytheon Technologies Corporation | Rotor assembly with internal vanes |
| US11371351B2 (en) | 2020-01-17 | 2022-06-28 | Raytheon Technologies Corporation | Multi-disk bladed rotor assembly for rotational equipment |
| US11286781B2 (en) | 2020-01-17 | 2022-03-29 | Raytheon Technologies Corporation | Multi-disk bladed rotor assembly for rotational equipment |
| US11401814B2 (en) | 2020-01-17 | 2022-08-02 | Raytheon Technologies Corporation | Rotor assembly with internal vanes |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5049578A (en) | 1990-03-09 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| CA2331735A1 (en) | 1998-05-08 | 1999-11-18 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
| WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| DE60015927T2 (de) | 1999-02-12 | 2005-04-07 | Smithkline Beecham P.L.C., Brentford | Phenylharnstoff und phenylthioharnstoffderivate |
| DE60013250T2 (de) | 1999-02-12 | 2005-09-08 | Smithkline Beecham P.L.C., Brentford | Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten |
| WO2000071511A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| WO2001085693A1 (en) | 2000-05-11 | 2001-11-15 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
| EP1289955B1 (en) | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| BR0209334A (pt) | 2001-05-05 | 2004-06-15 | Smithkline Beecham Plc | Aminas n-aroil cìclicas |
| US20040192673A1 (en) | 2001-05-05 | 2004-09-30 | Pascale Gaillard | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| JP4498922B2 (ja) | 2002-07-09 | 2010-07-07 | アクテリオン ファーマシューティカルズ リミテッド | ７，８，９，１０−テトラヒドロ−６Ｈ−アゼピノ、６，７，８，９−テトラヒドロ−ピリドおよび２，３−ジヒドロ−２Ｈ−ピロロ［２，１−ｂ］−キナゾリノン誘導体 |
| WO2004026866A1 (en) | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| NZ538749A (en) | 2002-10-11 | 2006-11-30 | Actelion Pharmaceuticals Ltd | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| AU2003299648A1 (en) | 2002-12-12 | 2004-06-30 | Janssen Pharmaceutica, N.V. | Substituted 4-phenyl-(1,3)-dioxanes |
| RU2345985C2 (ru) | 2003-03-26 | 2009-02-10 | Актелион Фармасьютиклз Лтд. | Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора |
| ATE383345T1 (de) | 2003-04-28 | 2008-01-15 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| HUP0304101A3 (en) | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| RU2378257C2 (ru) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
| WO2006067224A2 (en) | 2004-12-23 | 2006-06-29 | Biovitrum Ab (Publ) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists |
| CA2603766A1 (en) | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
| JP2008541698A (ja) | 2005-05-03 | 2008-11-27 | アンサンブル ディスカバリー コーポレイション | 核酸検出のためのターンオーバープローブおよびその使用 |
| US20090118200A1 (en) | 2005-05-23 | 2009-05-07 | Bergman Jeffrey M | Proline bis-amide orexin receptor antagonists |
| CA2617324A1 (en) | 2005-08-04 | 2007-02-15 | Merck & Co., Inc. | Aminoethane sulfonamide orexin receptor antagonists |
| JP2009506061A (ja) | 2005-08-26 | 2009-02-12 | メルク エンド カムパニー インコーポレーテッド | ジアザスピロデカンオレキシン受容体拮抗薬 |
| WO2007061763A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| CN101009515A (zh) | 2006-01-24 | 2007-08-01 | 华为技术有限公司 | 通信终端设备管理方法及通信终端 |
| TW200800020A (en) | 2006-01-26 | 2008-01-01 | Basf Ag | Methods to use 3-pyridyl derivatives as pesticides |
| FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
| JP2009533419A (ja) | 2006-04-11 | 2009-09-17 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルホンアミド化合物 |
| DE602007012072D1 (de) | 2006-04-26 | 2011-03-03 | Actelion Pharmaceuticals Ltd | Orantagonisten |
| WO2007143813A1 (en) | 2006-06-16 | 2007-12-21 | Husky Injection Molding Systems Ltd. | Preventative maintenance update system |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| SI2049529T1 (sl) | 2006-07-14 | 2010-11-30 | Merck Sharp & Dohme | Substituiran diazepan oreksin receptor antagonist |
| EP2049526A2 (en) | 2006-07-14 | 2009-04-22 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| CA2659299A1 (en) | 2006-08-15 | 2008-02-21 | Actelion Pharmaceuticals Ltd | Azetidine compounds |
| ATE458740T1 (de) | 2006-08-28 | 2010-03-15 | Actelion Pharmaceuticals Ltd | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten |
| CL2007002809A1 (es) | 2006-09-29 | 2008-04-18 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CN101568533A (zh) | 2006-12-01 | 2009-10-28 | 埃科特莱茵药品有限公司 | 3-异芳基(氨基或酰胺基)-1-(联苯或苯基噻唑基)羰基哌啶衍生物食欲素受体抑制剂 |
| AU2007337659A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| AR064561A1 (es) | 2006-12-28 | 2009-04-08 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| EP2131654A4 (en) | 2007-03-02 | 2011-02-02 | Merck Sharp & Dohme | Bipyridine-carboxamide-orexin receptor Antagonist |
| EP2114867B1 (en) | 2007-03-05 | 2012-12-12 | F. Hoffmann-La Roche AG | Aminoamides as orexin antagonists |
| AU2008225922B2 (en) | 2007-03-15 | 2012-04-26 | F. Hoffmann-La Roche Ag | Malonamides as orexin antagonists |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| CA2681163A1 (en) | 2007-04-04 | 2008-10-16 | F. Hoffmann-La Roche Ag | Heterocycles as orexin antagonists |
| US20100222328A1 (en) | 2007-05-14 | 2010-09-02 | Hamed Aissaoui | 2-cyclopropyl-thiazole derivatives |
| WO2008143856A1 (en) | 2007-05-18 | 2008-11-27 | Merck & Co., Inc. | Oxo bridged diazepan orexin receptor antagonists |
| HRP20120240T1 (hr) | 2007-05-23 | 2012-04-30 | Merck Sharp & Dohme Corp. | Piridil piperidin antagonisti receptora za oreksin |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| US8106215B2 (en) | 2007-07-03 | 2012-01-31 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.3.0]octane compounds |
| KR20100046047A (ko) | 2007-07-27 | 2010-05-04 | 액테리온 파마슈티칼 리미티드 | 2-아자-비시클로[3.3.0]옥탄 유도체 |
| EP2185512B1 (en) | 2007-07-27 | 2010-12-29 | Actelion Pharmaceuticals Ltd. | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| BRPI0814767A2 (pt) | 2007-08-02 | 2015-03-03 | Hoffmann La Roche | Derivados de monoamida como antagonistas do receptor de orexina |
| CA2695621A1 (en) | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| ES2560095T3 (es) | 2007-08-10 | 2016-02-17 | Cortex Pharmaceuticals, Inc. | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas |
| ES2400830T3 (es) | 2007-08-15 | 2013-04-12 | Actelion Pharmaceuticals Ltd. | Derivados de 1,2-diamido-etileno como antagonistas de orexina |
| US8288411B2 (en) | 2007-09-24 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
| EP2214676B1 (en) | 2007-10-29 | 2012-11-21 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| US8084464B2 (en) | 2007-12-18 | 2011-12-27 | Concert Pharmaceuticals, Inc. | Tetrahydroisoquinoline derivatives |
| KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
| ATE511500T1 (de) | 2008-01-21 | 2011-06-15 | Hoffmann La Roche | Sulfonamide als orexin-antagonisten |
| CN101918361B (zh) | 2008-02-12 | 2014-05-28 | 弗·哈夫曼-拉罗切有限公司 | 哌啶磺酰胺衍生物 |
| AU2009215243A1 (en) | 2008-02-21 | 2009-08-27 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo[2.2.1]heptane derivatives |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| CA2726102A1 (en) | 2008-06-11 | 2009-12-17 | Actelion Pharmaceuticals Ltd | Tetrazole compounds as orexin receptor antagonists |
| EP2297102A1 (en) | 2008-06-16 | 2011-03-23 | F. Hoffmann-La Roche AG | Heteroaromatic monoamides as orexinin receptor antagonists |
| KR20110036069A (ko) | 2008-06-25 | 2011-04-06 | 액테리온 파마슈티칼 리미티드 | 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물 |
| WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| JP5301665B2 (ja) | 2008-07-29 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | オレキシンアンタゴニストとしてのピロリジン−３−イルメチル−アミン |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| EP2161266A1 (en) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuran derivatives as orexin receptor antagonists |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| RU2011119217A (ru) | 2008-10-14 | 2012-11-27 | Актелион Фармасьютикалз Лтд | Производные фенетиламида и их гетероциклические аналоги |
| WO2010048013A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| AU2009307920A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| AU2009307915A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| AU2009307918A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| AU2009307921A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | Disubstituted azepan orexin receptor antagonists |
| JP2012506374A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト |
| EP2349267B1 (en) | 2008-10-30 | 2014-06-25 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| MX2011004551A (es) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| EP2349262B1 (en) | 2008-10-30 | 2014-06-25 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| KR20110091581A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도 |
| CA2745433A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Ltd. | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| JP2010155827A (ja) | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| AR077525A1 (es) | 2009-01-30 | 2011-09-07 | Novartis Ag | 4-aril-butan-1,3-diamidas y composiciones farmaceuticas |
| CN102459229A (zh) | 2009-04-24 | 2012-05-16 | 葛兰素集团有限公司 | 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷 |
| WO2011005636A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
| US20120149711A1 (en) | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| EP2470523A1 (en) | 2009-08-24 | 2012-07-04 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| EP2491031B1 (en) | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| EP2493299A4 (en) | 2009-10-29 | 2013-04-17 | Merck Sharp & Dohme | TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS |
| US20120258957A1 (en) | 2009-11-23 | 2012-10-11 | Matilda Jane Bingham | Heterocyclic derivatives |
| WO2011073316A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| US8530648B2 (en) | 2009-12-21 | 2013-09-10 | Novartis Ag | Diaza-spiro[5.5]undecanes |
| ES2460915T3 (es) | 2009-12-21 | 2014-05-16 | Novartis Ag | Piridinas fusionadas con heteroarilo disustituido |
| WO2011138266A1 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indolizine and imidazopyridine derivatives as orexin receptor antagonists |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| MX2013006715A (es) | 2010-12-17 | 2013-08-26 | Taisho Pharmaceutical Co Ltd | Derivado de pirazol. |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| US20120165331A1 (en) | 2010-12-22 | 2012-06-28 | Sangamesh Badiger | Di/tri-aza-spiro-C9-C11alkanes |
| WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| ES2541531T3 (es) | 2011-02-18 | 2015-07-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| US20140081025A1 (en) | 2011-05-10 | 2014-03-20 | Taisho Pharmaceutical Co., Ltd. | Heteroaromatic ring derivative |
| EP2730573A4 (en) | 2011-07-05 | 2014-12-03 | Taisho Pharmaceutical Co Ltd | METHYLPIPERIDINDERIVAT |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| WO2013059163A1 (en) | 2011-10-21 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2,5-disubstituted thiomorpholine orexin receptor antagonists |
| EP2771001A4 (en) | 2011-10-25 | 2015-03-25 | Merck Sharp & Dohme | PIPERIDINYL-alkyne-orexin |
| US9242995B2 (en) | 2011-10-25 | 2016-01-26 | Merck Sharp & Dohme Corp. | Isoxazolopyridine orexin receptor antagonists |
| SI2776430T1 (sl) | 2011-11-08 | 2016-06-30 | Actelion Pharmaceuticals Ltd. | 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja |
| ITMI20112329A1 (it) | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン |
| US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| ITMI20120322A1 (it) * | 2012-03-01 | 2013-09-02 | Rottapharm Spa | Composti di 4,4-difluoro piperidina |
| ITMI20120424A1 (it) | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| TW201613891A (en) | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
-
2015
- 2015-08-13 TW TW104126419A patent/TW201613902A/zh unknown
- 2015-08-13 AR ARP150102622A patent/AR101558A1/es unknown
- 2015-08-13 EP EP15832417.8A patent/EP3180332B1/en active Active
- 2015-08-13 WO PCT/US2015/044974 patent/WO2016025669A1/en not_active Ceased
- 2015-08-13 UY UY0001036272A patent/UY36272A/es not_active Application Discontinuation
- 2015-08-13 ES ES15832417T patent/ES2901418T3/es active Active
- 2015-08-13 US US15/503,131 patent/US10221170B2/en active Active
- 2015-08-13 JP JP2017506968A patent/JP6663909B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170226103A1 (en) | 2017-08-10 |
| WO2016025669A1 (en) | 2016-02-18 |
| ES2901418T3 (es) | 2022-03-22 |
| AR101558A1 (es) | 2016-12-28 |
| EP3180332A1 (en) | 2017-06-21 |
| UY36272A (es) | 2016-02-29 |
| US10221170B2 (en) | 2019-03-05 |
| EP3180332B1 (en) | 2021-10-27 |
| EP3180332A4 (en) | 2018-01-24 |
| TW201613902A (en) | 2016-04-16 |
| JP2017524005A (ja) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3180332B1 (en) | Difluoropyrrolidines as orexin receptor modulators | |
| JP7001682B2 (ja) | 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用 | |
| US12084437B2 (en) | Halo-substituted piperidines as orexin receptor modulators | |
| JP6130964B2 (ja) | Ａｐｊ受容体のトリアゾールアゴニスト | |
| EP2410858B1 (en) | P2x3 receptor antagonists for treatment of pain | |
| JP7862437B2 (ja) | オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物 | |
| JP6964576B2 (ja) | 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| EA037162B1 (ru) | 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj | |
| JP2015506382A (ja) | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン | |
| TW202542138A (zh) | 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途 | |
| HK40002227B (en) | Halo-substituted piperidines as orexin receptor modulators | |
| HK40002227A (en) | Halo-substituted piperidines as orexin receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180810 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190410 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190411 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190627 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190909 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200217 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6663909 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |